Alzheimer's disease drug US FDA approval and announcement Eisai jointly developed

The US FDA (Food and Drug Administration) announced on the 7th that it will approve a drug for Alzheimer's disease jointly developed by Eisai in Japan and Biogen, a pharmaceutical company in the United States.

The drug removes the abnormal protein "amyloid β" in the brains of patients with Alzheimer's disease to prevent nerve cells in the brain from breaking down and cognitive decline, according to the FDA. This is the first treatment for Alzheimer's disease.